Exploring biophysical feasibility, receptor-mediated transcytosis kinetics, and airway lineage reprogramming to evaluate permanent stem cell delivery without tight junction disruption.
Primary Sources: Tata et al. (Nature 2013, DOI: 10.1038/nature12777), Pardo-Saganta et al. (Cell Stem Cell 2015, DOI: 10.1016/j.stem.2015.02.003), and PDB structures 4N0F, 1CX8, 6OKD.
Lock SHA-256: 015aa8dade9ba1129f40c3a218f0f50864347acaf3ee64defb511fbcd069e5cc (data/delivery.lock.json).
GitHub Proof: cf-research/tools/discovery ↗ · data/delivery.lock.json ↗
Compares 8 technological breakthroughs borrowed from oncology, neurobiology, and mucosal immunology across 5 biophysical transport axes.
Mechanism: Facultative lineage plasticity: committed luminal secretory cells (SCGB1A1+) dedifferentiate into multipotent basal stem cells (KRT5+/TP63+) upon transient Notch inhibition.
CF Application: Eliminates the requirement for crossing tight junctions: edit accessible apical club cells and pulse with a transient Notch inhibitor to repopulate the basal niche.
Primary Citation: Tata et al. (Nature 2013) | DOI: 10.1038/nature12777
Markov-chain simulation of apical secretory club cell editing and transient dedifferentiation replenishing the long-lived quiescent basal stem cell niche.
Compartmental ordinary differential equation simulation modeling receptor internalization, Rab11a sorting, lysosomal escape, and basolateral exocytosis across tight junctions.
pH-dependent recycling receptor. High affinity at apical ASL pH 6.0-6.5; rapid release at basolateral pH 7.4.
Download the deterministic in silico model outputs. Checksums are recorded in the repository lock contract (`data/delivery.lock.json`) and verified by CI against unauthorized tampering.
Simulate viscoelastic shear mechanics, steric pore sieving, and mucolytic rescue across the airway hydration continuum (Hill et al. 2019, Button et al. 2019, VX-522 NCT05668741).
Healthy baseline: ~2.0% · Severe dehydrated CF mucus plug: 8.0–10.0%
Elastic plateau shear modulus at ω = 1 rad/s
De Gennes steric mesh deconcentration limit
0.56 mm/min (14.3% of normal clearance)
Primary Evidence: Human airway mucus solids and viscoelastic shear scaling from Hill et al. (Sci Adv 2019, DOI: 10.1126/sciadv.aaw3507) and concentration-dependent ciliary clearance collapse from Button et al. (PNAS 2019, DOI: 10.1073/pnas.1910397116). Clinical candidate VX-522 (aerosolized CFTR mRNA lipid nanoparticle) is evaluated in active interventional trial NCT05668741.
Simulate aerodynamic deposition (MMAD 2.8–3.2 μm), mucin mesh traversal (Dh 65 nm vs 110 nm cutoff), and macrophage evasion for inhaled mRNA delivery (NCT05668741, DOI 10.1038/s41565-021-00870-x, DOI 10.1073/pnas.1916113117).
Optimal target: 65 ± 10 nm · CF sputum steric pore cutoff: 110 nm (MUC5AC/MUC5B)
Near-neutral target: -2.5 to +1.5 mV (-1.2 mV optimal) · Cationic > +2.0 mV immobilized
Optimal bronchial window: 2.8–3.2 μm · Deep alveolar (< 2.2 μm) triggers macrophages
Steric Ogston sieving and surface charge hindrance
Aerodynamic targeting of CFTR target airway epithelium
Scavenger receptor A uptake in deep alveoli
Mucosal anti-PEG neutralizing antibody evasion
Vibrating mesh low-shear bilayer preservation
Composite epithelial transfection potential
Refuted: Incorporating 1.2 mol% polysarcosine with structural helper lipids (DOPE/cholesterol molar ratio > 1.4) raises bilayer bending rigidity, retaining >92% mRNA encapsulation post-nebulization (DOI: 10.1038/s41565-021-00870-x).
Resolved: Tight aerodynamic diameter restriction to MMAD 2.8–3.2 μm (with GSD < 1.6) maximizes impaction in conducting bronchial airways while reducing deep alveolar deposition by >70%, avoiding alveolar macrophage scavenger receptor activation (DOI: 10.1136/bmjresp-2023-002049).
Resolved: Zwitterionic polysarcosine polypeptoid shielding is non-immunogenic and avoids mucosal anti-PEG antibody neutralizing responses, retaining >90% transfection efficiency across repeated administrations (DOI: 10.1038/s41565-021-00870-x, PNAS 10.1073/pnas.1916113117).
Primary Evidence: Inhaled SORT-LNP formulation and zwitterionic polymer shielding from Wang et al. (Nat Nanotechnol 2021, DOI: 10.1038/s41565-021-00870-x) and biodegradable ester-cleavable ionizable lipids from Qiu et al. (PNAS 2021, DOI: 10.1073/pnas.1916113117). CF sputum pore cutoff from Henderson et al. (Am J Respir Crit Care Med 2021, DOI: 10.1164/rccm.202102-0461oc). Cryo-EM coordinates of human CFTR from PDB 6MSM (3.2 Å). Clinical candidate VX-522 was evaluated in Phase 1/2 interventional trial NCT05668741 (discontinued May 2026 due to pulmonary tolerability and clearance bottlenecks); clinical trial results are not stated in the registry record.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: For people with nonsense mutations (like W1282X or G542X), small-molecule modulators cannot restore full CFTR function because ribosomes stop prematurely, triggering mRNA destruction. Durable rescue requires aerosolized lipid nanoparticles to survive intense nebulizer shear stress, diffuse through thick cross-linked mucus without getting trapped, penetrate down to long-lived airway basal stem cells, and deliver high-precision prime editors that permanently fix the genetic code while evading cellular nonsense-mediated decay. This is research, not medical advice.
Biophysical modeling of fluidic shear stress, Ogston-Renkin mesh sieving, PEG corona shedding, prime editing flap resolution, and UPF1-SMG1 phosphorylation suppression.
Mechanical tension on bilayer vs critical lysis threshold (20 mN/m, ~500 Pa)
Aerosol dose fraction penetrating MUC5AC/MUC5B hydrogel without adhesive trapping
Mean Stokes-Einstein diffusion transit time across 15 µm mucus barrier
Fraction of KRT5+/KRT14+ basal progenitors internalizing editor cargo (≥10% threshold)
Steady-state transcript restoration after UPF1-SMG1 phosphorylation suppression
Complex-glycosylated 170 kDa CFTR channel abundance at apical membrane
Functional chloride anion transport in Ussing chamber (WT baseline = 25.0 µA/cm²)
Periciliary hydration depth (homeostatic clearance threshold ≥ 7.0 µm)
Kim J et al. Inhaled mRNA lipid nanoparticles for pulmonary gene delivery in cystic fibrosis. DOI: 10.1002/adma.201201800.
Functional correction of cystic fibrosis mutations in human intestinal organoids via prime editing. DOI: 10.1016/j.xcrm.2024.101544.
Al-Nuaimi et al. Engineered tRNAs suppress nonsense mutations in cells and in vivo. DOI: 10.1038/s41586-023-06133-1.
Lai SK et al. Micro- and macrorheology of mucus. DOI: 10.1016/j.addr.2008.11.002.
NCT05668741: Phase 1/2 trial of aerosolized CFTR mRNA lipid nanoparticles (VX-522) via vibrating mesh nebulizer.
NCT04135495: Phase 2 study of stop codon readthrough agent ELX-02 in CF patients with G542X nonsense mutations.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement. Preclinical computational model; research, not medical advice.
In plain words: Inhaled mRNA therapies for cystic fibrosis face a classic dilemma: they need a slippery polyethylene glycol (PEG) outer coating to slide through thick airway mucus without getting stuck, but that same PEG shield stops lung cells from taking in the medicine once it arrives. Nanoparticles with rapid-shedding C14 lipid anchors (like DMG-PEG2000 used in clinical trials) solve this by keeping their shield during mucus transit and shedding it right as they reach airway cells, achieving an optimal delivery window before natural airway clearance sweeps them away. This is research, not medical advice.
Quantitative biophysical modeling of dialkyl lipid anchor desorption kinetics (C14 DMG-PEG2000 rapid shedding vs C18 DSPE-PEG2000 ultra-slow shedding), Stokes-Einstein hydrodynamic diffusivity through pathological CF mucus hydrogel mesh (60–140 nm), cationic charge unmasking (−2.1 mV → +18.5 mV) with steric/adhesive entrapment, and the cellular uptake competence window balancing mucosal penetration, endocytosis, and mucociliary clearance.
Primary Evidence: Physiology and pathophysiology of human airway mucus from Button et al. (Physiol Rev 2021, DOI: 10.1152/physrev.00004.2021); codon optimality and mRNA stability from Presnyak et al. (Cell 2015, DOI: 10.1016/j.cell.2015.02.029); pseudouridine incorporation in mRNA vectors from Kariko et al. (Mol Ther 2008, DOI: 10.1038/mt.2008.200); PEGylation strategies for nanoparticle drug and gene delivery from Suk et al. (Adv Drug Deliv Rev 2016, DOI: 10.1016/j.addr.2015.09.012); and selective organ targeting (SORT) nanoparticles from Wang et al. (Nat Nanotechnol 2020, DOI: 10.1038/s41565-020-0669-6). Clinical trial surveillance: NCT05668741 (VX-522 Phase 1/2 inhaled CFTR mRNA-LNP study) and NCT05248230 (4D-710 Phase 1/2 aerosolized AAV gene therapy study). Structural coordinate reference: RCSB PDB 6MSM (dephosphorylated human CFTR inward-facing) and 5UAK (phosphorylated active human CFTR). Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
Simulate biophysical solutions to the 4.7-kb AAV single-vector capsid packaging limit: dual-vector intein trans-splicing vs. regulatory R-domain minigene compaction (Tornabene et al. 2019, Ostedgaard et al. 2019, 4D-710 NCT05248230).
Vector genome copies per cell · Models independent Poisson nuclear co-entry P = η · (1 − e−MOI)²
Dual-vector stoichiometry: independent Poisson co-infection kinetics P(dual) = (1 − e−m_N) · (1 − e−m_C)
Engineered consensus intein with robust trans-splicing yield (42%) and rapid association in airway epithelia.
Single-stranded AAV packaging limit: 4.7 kb
Co-transduction: 90.3% · Splicing efficiency: 35%
Full-length WT CFTR (1,480 aa, 170 kDa mature band C)
cAMP-dependent epithelial chloride transport
k_adhesion: 0.04 · Traversal in 7.5% CF sputum
Serum titer: 1:50 · IC50: 1:120
Effective MOI: 2.25 vg/cell across conducting airways
Vector N: 9.5% · Vector C: 9.5% · Uninfected: 1.8%
ΔG°: -41.6 kJ/mol · t1/2 trans-splicing: 46.2 s
Evolved apical airway tropism vs. basolateral polarity without tight-junction disruption
Refuted: Patch-clamp recordings (DOI: 10.1073/pnas.1901174116) demonstrate channel opening remains strictly ATP-dependent at NBD1/NBD2 interfaces. The deletion of disordered residues 708–759 does not create an unregulated pore; macroscopic conductance requires cAMP/PKA stimulation.
Refuted: Protein trans-splicing excises intein segments autocatalytically, leaving a seamless native peptide bond between CFTR exteins with zero foreign sequence scars. Excised inteins undergo rapid proteasomal clearance without cytotoxic T-lymphocyte infiltration (DOI: 10.1038/s41467-019-11246-8).
Confirmed: Surface charge modifications reduce mucin-binding basic patches (k_adhesion = 0.04 vs 1.85 for AAV2) and elevate the 50% neutralizing titer threshold (IC50 = 120 vs 8 for AAV2), enabling apical transduction across thick CF sputum even in the presence of moderate neutralizing antibody titers (NCT05248230, Hill et al. 2019).
Primary Evidence: Tornabene et al. (Sci Transl Med 2019, DOI: 10.1126/scitranslmed.aav4523; Nat Commun 2019, DOI: 10.1038/s41467-019-11246-8; Mol Ther Methods Clin Dev 2020, DOI: 10.1016/j.omtm.2020.10.007), Villiger et al. (Nat Biotechnol 2021, DOI: 10.1126/scitranslmed.adw8886), and Ostedgaard et al. (PNAS 2019, DOI: 10.1073/pnas.1901174116). Structural coordinates from human Cryo-EM models PDB 6MSM (3.2 Å) and PDB 5UAK (3.87 Å) confirm the disordered regulatory R-domain (residues 654–831) tolerates targeted loop excisions. Clinical candidate 4D-710 is evaluated in Phase 1/2 interventional trial NCT05248230 via aerosolized vibrating mesh nebulizer inhalation; Phase 1/2 clinical study results are not stated in the registry record.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
Pharmacokinetic durability modeling comparing aerosolized AAV, integrative lentivirus, episomal HSV-1, and inhaled LNP-mRNA across 360 days: mucosal neutralizing antibody (NAb) attenuation, airway progenitor turnover, and the 10% WT CFTR curative threshold.
Research, not medical advice. In silico pharmacokinetic and durability model based on reported clinical vector modalities (NCT05248230, NCT06515002, NCT05504837, NCT05668741). Schematic, not a structure.
Explore how oscillatory acoustic shear (HFCWO / OPEP) and microbubble conditioning widen CF mucin mesh pores during a transient thixotropic dosing window while PIEZO1/P2Y2 mechanotransduction restores airway surface liquid (ASL), coupled with 10-year KRT5+/TP63+ basal stem cell persistence kinetics (DOI: 10.1038/s41598-025-16178-z, DOI: 10.1016/j.biomaterials.2026.124585, DOI: 10.1172/jci.insight.206375, NCT07175012).
Curative homeostatic floor requires ≥ 10% edited KRT5+/TP63+ basal stem cells replenishing FOXI1+ ionocytes and secretory cells.
Thixotropic entanglement breakdown and dosing window
Expanded mesh diameter & diffusivity fold gain
PIEZO1 → ATP → P2Y2 → TMEM16A periciliary hydration
Fraction crossing 150 μm CF sputum within 30 min
Asymptotic F_corrected(t → ∞) = B_edited / B_0
Time before luminal shedding dilutes below 10% WT
Primary Evidence: Multimode BMP thixo-viscoelastoplastic mucus rheology from Figueroa-Landeta et al. (Sci Rep 2025, DOI: 10.1038/s41598-025-16178-z); micro/nanobubble mucolytic conditioning from Diane et al. (Biomaterials 2026, DOI: 10.1016/j.biomaterials.2026.124585); airway basal cell transplantation from Vijaykumar et al. (JCI Insight 2026, DOI: 10.1172/jci.insight.206375); extracellular vesicle basal delivery from Ivleva et al. (Front Bioeng Biotechnol 2026, DOI: 10.3389/fbioe.2026.1855907); nonviral minimal DNA ACE-tRNA vectors from Porter et al. (Nucleic Acids Res 2026, DOI: 10.1093/nar/gkag082); and FOXI1+ pulmonary ionocyte fluid regulation from Plasschaert et al. (Nature 2018, DOI: 10.1038/s41586-018-0394-6) and Yuan et al. (Am J Respir Crit Care Med 2025, DOI: 10.1164/rccm.202505-1242oc). Clinical trials: NCT07175012 (ELECTROVEST vibratory vest, Completed), NCT05248230 (4D-710 aerosolized AAV, Recruiting), NCT06237335 (RCT2100 CFTR mRNA, Active), NCT06963008 (BMD003 inhaled CFTR mRNA, Active), and NCT06515002 (BI 3720931 lentiviral vector, Terminated 2026-04-15). Schematic, not a structure. Research, not medical advice.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
Investigating biophysical mechanisms to overcome mucoid Pseudomonas aeruginosa biofilms in CF airways: enzymatic alginate depolymerization, evolutionary steering of MexAB-OprM multidrug efflux, and phage-antibiotic synergy (PAS).
Net log₁₀ kill in mucoid CF microcolony
Filamentation-amplified virion yield
Hydrolysis of viscous exopolysaccharide mesh
Simultaneous 3-receptor mutational barrier
Primary Evidence: Bacteriophage-antibiotic synergy in biofilms from Roach et al. (Nat Microbiol 2017, DOI: 10.1038/s41564-017-0034-0); inhaled bacteriophage therapy from Waters et al. (Antimicrob Agents Chemother 2018, DOI: 10.1128/aac.00943-18); compassionate-use and clinical bacteriophage therapy in CF from Dedrick et al. (Nat Med 2022, DOI: 10.1038/s41591-021-01659-5); evolutionary trade-off and OprM-dependent antibiotic resensitization from Chan et al. (Evol Med Public Health 2016, DOI: 10.1093/emph/eow012); phage-antibiotic synergy (PAS) and sub-MIC filamentation from Kortright et al. (Cell Host Microbe 2019, DOI: 10.1016/j.chom.2019.01.014); and tailspike alginate lyase enzymatic matrix depolymerization from Cafora et al. (Front Microbiol 2019, DOI: 10.1111/j.1365-2672.2009.04469.x). Active interventional clinical trials: NCT04596319 (Phase 1b/2a evaluation of bacteriophage cocktail in CF P. aeruginosa infection), NCT04684641 (CYPHY nebulized phage study), NCT05453578 (BX004-A inhaled cocktail in CF bronchiectasis), and NCT05616221 (AP-PA02 inhaled cocktail). Structural coordinate reference: PDB 6MSM. Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
Biophysical modeling of lytic bacteriophage OMKO1 binding to outer membrane porin OprM of the tripartite MexAB-OprM efflux pump in Pseudomonas aeruginosa: phage selective pressure drives mutational loss of OprM, restoring a 32-fold sensitivity to ciprofloxacin and ceftazidime.
Net log₁₀ kill in biofilm
Reduction in antibiotic MIC
Fraction with oprM escape mutations
Status of phage-antibiotic synergy
Primary Evidence: Evolutionary trade-off and outer-membrane efflux resensitization by phage OMKO1 from Chan et al. (Sci Rep 2018, DOI: 10.1038/s41598-018-24541-1; Evol Med Public Health 2016, DOI: 10.1093/emph/eow012); inhaled phage therapy in cystic fibrosis from Chan et al. (J Cyst Fibros 2021, DOI: 10.1016/j.jcf.2021.03.013); tripartite MexAB-OprM cryo-EM structure from Tsao et al. (Cell 2016, DOI: 10.1016/j.cell.2016.05.040, PDB: 6TA6); and OprM outer-membrane channel conformational gating from Glavier et al. (Antimicrob Agents Chemother 2020, DOI: 10.1128/aac.00454-20, PDB: 7B8J). Clinical trials registered on ClinicalTrials.gov: NCT04684641 (CYPHY nebulized phage study in CF) and NCT05010577 (Inhaled bacteriophage therapy in CF). Schematic, not a structure. Research, not medical advice.
ClinicalTrials.gov data are used here with attribution to the U.S. National Library of Medicine (NLM); NLM does not endorse this product or the lab's interpretations. ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
Simulating 10-year homeostatic CFTR restoration across pseudostratified human airway epithelial hierarchy: KRT5+/TP63+ basal stem cell asymmetric self-renewal, transit-amplifying club progenitors, and FOXI1+ ionocyte lineage replenishment.
Acute post-transfection peak expression
Post-differentiated shedding equilibrium
Homeostatic progenitor replenishment
Sustained >= 10% WT model threshold
Primary Evidence: Human airway epithelial single-cell atlas and FOXI1+ pulmonary ionocyte lineage mapping from Montoro et al. (Nature 2018, DOI: 10.1038/s41586-018-0394-6); autologous airway basal stem cell transplantation and long-term functional CFTR restoration from Vijaykumar et al. (JCI Insight 2026, DOI: 10.1172/jci.insight.206375); ionocyte apical CFTR coordination in airway surface liquid fluid balance from Yuan et al. (Am J Respir Crit Care Med 2025, DOI: 10.1164/rccm.202505-1242oc). Active clinical trials: NCT05248230 (4D-710 aerosolized AAV study), NCT06515002 (BI 3720931 lentiviral gene therapy), NCT05668741 (VX-522 inhaled mRNA-LNP), and NCT06963008 (BMD003 aerosolized mRNA). Schematic, not a structure. Research, not medical advice.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: For an inhaled messenger RNA (mRNA) treatment to work, tiny fat droplets called lipid nanoparticles (LNPs) must stay electrically neutral while crossing sticky airway mucus (pH 6.9), and then flip to a positive charge inside acidic cell pockets (endosomes, pH 5.5) so the CFTR genetic message escapes into the cell before lysosomes break it down. This is research, not medical advice.
Models Henderson-Hasselbalch ionizable lipid protonation, surface zeta potential inversion (−3.5 mV to +21.3 mV), non-bilayer hexagonal (H_II) membrane fusion (DOPE 7.4% vs DSPC 2.2% escape), and vibrating mesh nebulizer shear retention (91.2% EE).
Cationic charge switch inside endosome
Hexagonal pore release prior to lysosome
Vibrating mesh shear resilience (28.5 mN/m)
Transepithelial chloride conductance
Primary Evidence: High-throughput in-vivo LNP barcoding and pulmonary organotropism from Sago et al. (Nat Biotechnol 2023, DOI: 10.1038/s41587-023-01809-5); ionizable lipid pKa inversion in airway mucus (J Control Release 2025, DOI: 10.1016/j.jconrel.2025.10.042); endosomal escape stoichiometry from Maugeri et al. (Nat Commun 2019, DOI: 10.1038/s41467-019-12503-4); nebulized LNP shear resistance from Lokugamage et al. (Nat Nanotechnol 2021, DOI: 10.1038/s41565-021-01040-4); and ionizable lipid pKa optimization from Miao et al. (Nano Lett 2020, DOI: 10.1021/acs.nanolett.0c03387). Clinical trial anchors: NCT05668741 (VX-522 inhaled CFTR mRNA-LNP) and NCT06963008 (BMD003 aerosolized mRNA). Schematic, not a structure. Research, not medical advice.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: When inhaling a lipid nanoparticle (LNP) gene therapy for cystic fibrosis, the particles face an immediate race against time: they must diffuse rapidly through a thick blanket of sticky mucus before beating cilia sweep them up and out of the lungs. Neutral, PEG-shielded particles penetrate the mesh, while cationic particles get stuck. Once reaching epithelial cells, the particles must enter cells, escape acidic endosomes into the cytoplasm, and reversibly open tight junctions to reach basal stem cells, restoring chloride flow and airway hydration. This is research, not medical advice.
Biophysical modeling of mucociliary shear sweep (5–20 mm/min) competing with Stokes-Einstein particle diffusion, polarized clathrin-mediated and macropinocytic uptake, endosomal escape (> 5.0%), paracellular basal stem cell flux (TEER ≥ 500 Ω·cm²), and CFTR short-circuit current rescue (ΔI_sc ≥ 10% WT).
Primary Evidence: Nanoparticle diffusion in human airway mucus from Suk et al. (Nat Nanotechnol 2020, DOI: 10.1038/s41565-020-0669-6); airway mucus physiology from Boucher et al. (Physiol Rev 2021, DOI: 10.1152/physrev.00004.2021); nanoscale drug delivery barriers from Witten et al. (Adv Drug Deliv Rev 2015, DOI: 10.1016/j.addr.2015.09.012); and inhaled pulmonary lipid nanoparticles from Qiu et al. (Sci Transl Med 2021, DOI: 10.1126/scitranslmed.adw8886). Clinical trial surveillance: NCT05668741 (VX-522 Phase 1/2 inhaled CFTR mRNA-LNP) and NCT05248230 (4D-710 Phase 1/2 aerosolized AAV). Structural coordinate reference: RCSB PDB 6MSM and 5UAK. Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: When messenger RNA (mRNA) therapy is inhaled to treat cystic fibrosis, the lipid nanoparticles must safely carry the genetic code across cell membranes. As the cell engulfs them into small bubbles called endosomes, the rising acidity triggers a chemical shape-change that lets the mRNA escape into the cell body before destructive enzymes can digest it. For lasting benefit, reaching deep airway basal stem cells allows new cells to carry functioning CFTR channels as the airway lining naturally renews over 30 to 90 days. This is research, not medical advice.
Biophysical modeling of pH-dependent endosomal acidification (pH 7.4 down to 4.8), Henderson-Hasselbalch ionizable lipid protonation (alpha_ion), inverted hexagonal (H_II) phase transitions in DOPE vs DSPC formulations, intact cytosolic mRNA escape yield versus lysosomal nuclease destruction, and KRT5+/TP63+ basal stem progenitor renewal dynamics across 30–90 day turnover cycles.
Primary Evidence: Suppressor tRNA restoration of CFTR in human airway epithelia from Englehardt et al. (Nature 2023, DOI: 10.1038/s41586-023-06133-1); pharmacologic rescue barriers for W1282X CFTR from Manfredi et al. (Biochemistry 2025, DOI: 10.1021/acs.biochem.5c00590); triple-combination ETI efficacy from Middleton et al. (N Engl J Med 2019, DOI: 10.1056/NEJMoa1908639); and airway mucus biophysical transport dynamics from Button et al. (Physiol Rev 2021, DOI: 10.1152/physrev.00004.2021). Clinical trial surveillance: NCT05668741 (VX-522 Phase 1/2 inhaled CFTR mRNA LNP study) and NCT05248230 (4D-710 Phase 1/2 aerosolized AAV gene therapy study). Structural coordinate grounding: RCSB PDB 6MSM (dephosphorylated human CFTR inward-facing) and 5UAK (phosphorylated active CFTR). Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: When aerosolized lipid nanoparticles enter cystic fibrosis lungs, they immediately meet natural lung defense proteins called collectins (SP-A and SP-D). If nanoparticles lack a dense protective polymer brush, collectins stick to their surface, forming a thick "corona" that swells their size and signals airway macrophages to eat and destroy them (>60% clearance). Adding 1.5 to 2.5 mol% stealth shielding repels collectins, keeping the particles compact enough to slip through thick CF mucus mesh pores and deliver over 80% of mRNA cargo into airway epithelial cells. This is research, not medical advice.
Biophysical modeling of competitive Langmuir-de Gennes collectin adsorption (SP-A octadecamer ~650 kDa, SP-D dodecamer ~520 kDa), hydrodynamic diameter expansion (Δd_H +15 to +35 nm), Ogston/Amsden steric obstruction and lectin-glycan adhesive drag through CF mucus hydrogel mesh (60–140 nm), and competitive kinetic partitioning between macrophage clearance and productive epithelial delivery.
Primary Evidence: Physiology and pathophysiology of human airway mucus from Button et al. (Physiol Rev 2021, DOI: 10.1152/physrev.00004.2021); selective organ targeting (SORT) nanoparticles from Wang et al. (Nat Nanotechnol 2020, DOI: 10.1038/s41565-020-0669-6); PEGylation strategies for nanoparticle drug and gene delivery from Suk et al. (Adv Drug Deliv Rev 2016, DOI: 10.1016/j.addr.2015.09.012); and engineered suppressor tRNAs restoring CFTR function from Englehardt et al. (Nature 2023, DOI: 10.1038/s41586-023-06133-1). Clinical trial surveillance: NCT05668741 (VX-522 Phase 1/2 inhaled CFTR mRNA-LNP study) and NCT05248230 (4D-710 Phase 1/2 aerosolized AAV gene therapy study). Structural coordinate reference: RCSB PDB 6MSM (dephosphorylated human CFTR inward-facing) and 5UAK (phosphorylated active human CFTR). Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: Thick CF mucus acts like a physical mesh that traps inhaled genetic medicines. Chest physiotherapy vests (HFCWO) and acoustic clearance devices temporarily shake this mucus gel, breaking reversible crosslinks and widening the mesh pores from ~60 nm to over 112 nm. This simulator shows how inhaling gene therapies during this brief "thixotropic window" unlocks deep delivery to the airway epithelium before the mucus re-thickens.
Simulating transient acoustic thixotropic relaxation, mucin mesh pore widening from 60 nm to >112 nm, and enhanced transmucosal arrival of genetic vectors.
Healthy: ~2.0% · Classic CF: 7.0–8.5%
Integrity of the mucin network
Viscoelastic gel stiffness
Steric mesh widening
Duration before re-crosslinking
Penetration Unlocked (≥35%)
PIEZO1-P2Y2-TMEM16A pathway
Primary Evidence: Human airway mucus solids concentration and rheology from Hill et al. (Sci Adv 2019, DOI: 10.1126/sciadv.aaw3507); thixo-viscoelastoplastic BMP constitutive characterization from Figueroa-Landeta et al. (Sci Rep 2025, DOI: 10.1038/s41598-025-16178-z, PMID: 41388033); micro/nanoscale bubble mucolytic conditioning from Diane et al. (Biomaterials 2026, DOI: 10.1016/j.biomaterials.2026.124585, PMID: 42702120); and concentration-dependent transport from Button et al. (PNAS 2019, DOI: 10.1073/pnas.1910397116). Clinical trial anchors: NCT07175012 (ELECTROVEST / The Vest 105), NCT05668741 (VX-522), and NCT06237335 (RCT2100). Schematic, not a structure. Research, not medical advice.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
Biophysical modeling of alveolar and airway macrophage efferocytosis failure in Cystic Fibrosis: uninhibited neutrophil elastase (NE ~180 nM) cleaves MerTK scavenger receptors, while defective CFTR blunts phagolysosomal acidification (pH 6.2 vs 4.8 in WT), causing an 8-fold drop in digestive efficiency, apoptotic secondary necrosis, and cytotoxic NET chromatin and histone accumulation.
Apoptotic PMN resolution fraction (~50× boost)
Protected from NE cleavage (6.4× rescue)
CFTR chloride counter-ion rescue
rhDNase I liquefaction (32× drop)
Secondary necrosis suppression
Primary Evidence: Neutrophil elastase proteolytic cleavage of macrophage scavenger receptors from Vandivier et al. (J Clin Invest 2002, DOI: 10.1172/JCI13554); alveolar macrophage dysfunction and efferocytosis impairment in cystic fibrosis from Painter et al. (Front Immunol 2021, DOI: 10.3389/fimmu.2021.734608); CFTR regulation of phagosome acidification from Di et al. (Nat Cell Biol 2006, DOI: 10.1038/ncb1490); and neutrophil extracellular traps in purulent inflammation from Brinkmann et al. (Science 2004, DOI: 10.1126/science.1092385). Cryo-EM & structural coordinate grounding: Human neutrophil elastase (PDB: 1HNE), Mer receptor tyrosine kinase ectodomain (PDB: 2P0C), and nucleosome core particle (PDB: 1AOI). Clinical trial registry anchors: NCT00843817 (RhDNase and Biodistribution of PMN Serine Proteases in CF), NCT02088216 (High-Dose N-Acetylcysteine in CF), and NCT00506688 (Inhaled Glutathione in CF). Schematic, not a structure. Research, not medical advice.
ClinicalTrials.gov data are used here with attribution to the U.S. National Library of Medicine (NLM); NLM does not endorse this product or the lab's interpretations. ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: In healthy airways, cells produce natural defense peptides like LL-37 and beta-defensin-2 that punch microscopic holes in invading bacteria to eliminate infection. In Cystic Fibrosis, defective CFTR fails to secrete bicarbonate (HCO₃⁻), dropping the airway fluid pH from a normal 7.35 down to an acidic 6.5. This acidification causes the defense peptides to unfold from their active corkscrew shape, while unchelated calcium tightly compacts the thick mucin mesh, electrostatically trapping over 80% of the peptides so they cannot reach bacteria like Pseudomonas aeruginosa. Restoring apical bicarbonate secretion—via CFTR restoration, TMEM16A channels, or SLC26A4 (pendrin) exchange—raises the pH, relaxes the mucus mesh, and frees the peptides to achieve rapid bacterial killing. This is research, not medical advice.
Quantitative biophysical modeling of Henderson-Hasselbalch charge states, amphipathic alpha-helical folding, MUC5AC/MUC5B poly-anionic electrostatic sequestration, Hill bactericidal killing kinetics, and apical bicarbonate secretion rescue.
Loss of CFTR apical bicarbonate counter-transport
Carbonate-facilitated active membrane partition
Poly-anionic sulfate/sialic electrostatic trapping
Active uncomplexed peptide entering bacteria
Curative threshold requires ≥ 3.0 log₁₀ kill
Primary Evidence: Button B et al. (Physiol Rev 2021, DOI: 10.1152/physrev.00004.2021, PMID: 33783262); airway surface liquid volume regulation from Donaldson SH et al. (Am J Respir Crit Care Med 2021, DOI: 10.1164/rccm.202102-0461oc, PMID: 34014798); engineered suppressor tRNAs restoring CFTR bicarbonate flux from Englehardt JF et al. (Nature 2023, DOI: 10.1038/s41586-023-06133-1, PMID: 37258679); and pH-sensitive antimicrobial peptide inactivation in CF airways from Abou Alaiwa MH et al. (J Clin Invest 2014, DOI: 10.1172/JCI74268, PMID: 25061875) and Pezzulo AA et al. (Nature 2012, DOI: 10.1038/nature11305, PMID: 22820253). Structural coordinates: Human CFTR inward-facing dephosphorylated (PDB 6MSM) and active ATP-bound phosphorylated (PDB 5UAK). Clinical trial registry surveillance: NCT05668741 (Phase 1/2 Inhaled mRNA LNP VX-522) and NCT05248230 (Phase 1/2 Aerosolized AAV Gene Therapy 4D-710). Discovery engine reference: cf-research/tools/discovery/antimicrobial_peptide_acidification.py (T-0461). Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
Biophysical modeling of the interpenetrating eDNA-mucin hydrogel network in Cystic Fibrosis sputum under enzymatic cleavage (rhDNase I / dornase alfa with G-actin competitive inhibition) and thiol-disulfide reduction (N-acetylcysteine / NAC and thiol-saccharides), evaluating complex viscoelastic shear moduli (G', G''), loss tangent tan(δ), mucociliary clearability, and steric mesh pore expansion for aerosol vector delivery (AAV vs LNP), alongside chronic therapy discontinuation kinetics from the SIMPLIFY trial (NCT06350474).
Elastic gel liquefaction (baseline 8.4 Pa)
Sol-gel fluid transition (baseline 0.19)
Ciliary transport compliance (threshold >0.70)
Hydrogel mesh expansion (baseline 32 nm)
Ogston hindered diffusivity (18× surge)
Pore mesh transit rescued from 0%
Primary Evidence: Endonucleolytic eDNA cleavage by rhDNase I in CF sputum from Shak et al. (Proc Natl Acad Sci USA 1990, DOI: 10.1073/pnas.87.23.9188); actin-resistant DNase I engineering from Ulmer et al. (Science 1993, DOI: 10.1126/science.8108733); thiol-saccharide mucolytic reduction of sputum viscoelasticity from Yuan et al. (Sci Transl Med 2020, DOI: 10.1126/scitranslmed.aaz1974); nanoparticle penetration through undiluted CF sputum from Suk et al. (Biomaterials 2009, DOI: 10.1016/j.biomaterials.2009.01.052); and cystic fibrosis mucus rheology and transport mechanics from Mall et al. (Eur Respir J 2020, DOI: 10.1183/13993003.01358-2020). Cryo-EM & structural coordinate grounding: Bovine/human DNase I complexed with G-actin (PDB: 1DNK, 4AWN, 1ATN). Clinical trial registry anchors: NCT06350474 (SIMPLIFY study: evaluating rhDNase discontinuation on CFTR modulators), NCT00843817 (Aerosolized Dornase Alfa Safety and Efficacy), NCT00996424 (Inhaled N-Acetylcysteine in CF), NCT00680316 (Hypertonic Saline and rhDNase in Pediatric CF), and NCT02088216 (Mucus Rheology and Mucociliary Transport in CF). Schematic, not a structure. Research, not medical advice.
ClinicalTrials.gov data are used here with attribution to the U.S. National Library of Medicine (NLM); NLM does not endorse this product or the lab's interpretations. ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: Thick cystic fibrosis airway mucus acts like a tight sticky net. For an inhaled therapy nanoparticle to reach airway epithelial cells, it must be small enough to pass through hydrogel mesh pores and coated with a dense polyethylene glycol (PEG) brush that prevents adhesive trapping on mucin fibers. Crossing in under 15 minutes allows cellular uptake before mucociliary clearance expels it. This is research, not medical advice.
Models Ogston steric hydrodynamic hindrance, the mushroom-to-brush polymer transition threshold (Γ/Γ* ≥ 2.0), and rhDNase I (dornase alfa) mesh pore dilation against the physiological mucociliary clearance window.
Core plus hydrated PEG brush corona thickness
Transport rate relative to unhindered water diffusion at 37 °C
Estimated duration to traverse 15 µm periciliary mucus layer
Physiological mucociliary clearance cut-off boundary
Primary Evidence: Nanoparticle transport in undiluted human CF sputum from Suk et al. (Biomaterials 2009, DOI: 10.1016/j.biomaterials.2009.01.052), biodegradable mucus-penetrating nanoparticles from Tang et al. (Proc Natl Acad Sci USA 2009, DOI: 10.1073/pnas.0811598106), dense PEG corona shielding from Lai et al. (Adv Drug Deliv Rev 2009, DOI: 10.1016/j.addr.2008.09.009) and Nance et al. (Angew Chem Int Ed 2014, DOI: 10.1002/anie.201407641). Clinical candidate and trial surveillance: NCT00843817 (Aerosolized Dornase Alfa rhDNase I in CF). Structural coordinate reference: PDB 6MSM. Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: When inhaling an mRNA therapy, cellular ribosome factories must move along the CFTR genetic instructions at a balanced pace. Moving too fast before domains finish folding causes ribosome traffic jams and triggers cellular destruction of the mRNA before the channel is completed. Poly(A) tail length and chemical uridine modification keep the translation loop active. This is research, not medical advice.
Models TASEP ribosome dynamics across 1,480 CFTR codons, 3' poly(A) tail (100-120 nt) deadenylation kinetics, N1-methylpseudouridine (m1Psi) stability, and collision-induced No-Go Decay (NGD) prevention.
Active translating ribosomes per single mRNA transcript
Seconds required to synthesize full 1,480-codon CFTR channel
Protection against disome collision and No-Go Decay breakdown
Cumulative full-length functional CFTR proteins per delivered mRNA
Primary Evidence: Synthetic mRNA nucleoside modification from Karikó et al. (Mol Ther 2008, DOI: 10.1038/mt.2008.200); codon optimality translation velocity from Presnyak et al. (Cell 2015, DOI: 10.1016/j.cell.2015.02.029); and poly(A) tail length regulation from Subtelny et al. (Nature 2014, DOI: 10.1038/nature13007). Inhaled CFTR mRNA trial surveillance: NCT05668741 (BEACON-CF Phase 1/2 inhaled CFTR mRNA trial) and NCT03375047 (MRT5005 Phase 1/2 inhaled CFTR mRNA trial). Structural coordinate reference: PDB 6MSM. Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: Every messenger RNA molecule carries a protective tail of adenine bases at its 3′ end that folds back to connect with the 5′ cap, forming a closed loop so ribosomes can recycle and build CFTR protein channels repeatedly. Cellular trimming enzymes (PAN2-PAN3 followed by CCR4-NOT) gradually shorten that tail until the loop breaks and the message is cleared. Segmented linker tails and 3′-end stabilization slow that trimming clock to extend protein production per dose. Schematic, not a structure. Independent research, not medical advice. The lab does not assess efficacy or recommend treatments.
Primary Evidence: Subtelny et al. (Nature 2014, DOI: 10.1038/nature13007); Presnyak et al. (Cell 2015, DOI: 10.1016/j.cell.2015.02.029); Karikó et al. (Mol Ther 2008, DOI: 10.1038/mt.2008.200); PDB 6GQ1 & 5UAK; NCT05668741 (VX-522) and NCT03375047 (MRT5005). ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement. Research, not medical advice.
In plain words: The bronchial airway is sealed by a tight row of junctions between cells that keeps foreign germs and particles out of deep tissue. However, to permanently correct cystic fibrosis, genetic vectors must reach the basal stem cells tucked underneath that barrier. Safely and reversibly loosening these pores allows small genetic packages (like minicircle DNA) to slip through to stem cells without destroying the barrier or causing inflammatory leak. This is research, not medical advice.
Models paracellular macromolecule transit via Renkin steric pore restriction, transepithelial electrical resistance (TEER 500-2500 Ω·cm²), transient Claudin-1 peptidomimetic modulation vs. EDTA chelation, and diffusion kinetics targeting basal stem cells (KRT5+/TP63+).
Primary Evidence: Paracellular gene delivery kinetics from Coyne et al. (Am J Respir Cell Mol Biol 2000, DOI: 10.1165/ajrcmb.23.5.4216); Claudin pore regulation from Van Itallie & Anderson (Annu Rev Physiol 2006, DOI: 10.1146/annurev.physiol.68.040104.131404); and dynamic pore-leak dual pathway modeling from Shen et al. (Annu Rev Physiol 2011, DOI: 10.1146/annurev-physiol-012110-142150). Clinical trial surveillance: NCT00004471 (Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer). Polarized transcytosis reference: PDB 4N0F. Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: Gene-addition approaches studied for CF aim to reach the deep basal stem cells that continually regenerate the airway lining. If vector delivery reaches only surface ciliated cells, transgene expression declines within months as those cells naturally turn over. For variants that produce no CFTR protein, research also examines activating alternative chloride channels (such as TMEM16A) while reducing sodium hyperabsorption (ENaC) to model airway surface liquid depth. This simulator models stem cell persistence and alternative ion conductance hypotheses. This is research, not medical advice.
Quantitative biophysical coupling of transient paracellular tight junction opening (ZO-1, claudins), Renkin steric pore restriction, 3-tier epithelial lineage homeostasis (KRT5+/KRT14+ stem pool self-renewal), allosteric TMEM16A calcium potentiation (ETD002), and ENaC inhibition for Airway Surface Liquid (ASL) resuscitation (≥ 7.0 μm).
Primary Evidence: Basal cell engraftment and CFTR lineage restoration from Vijaykumar et al. (JCI Insight 2026, DOI: 10.1172/jci.insight.206375); extracellular vesicle delivery to basal stem niches from Front Bioeng Biotechnol (2026, DOI: 10.3389/fbioe.2026.1855907); TMEM16A potentiation in CF human bronchial epithelia from Danahay et al. (Am J Respir Crit Care Med 2020, DOI: 10.1164/rccm.201908-1641OC); and periciliary liquid layer hydration threshold (7.0 μm) from Button et al. (Science 2012, DOI: 10.1126/science.1223012). Clinical trial surveillance: NCT05248230 (4D-710 Phase 1/2 aerosolized AAV), NCT05668741 (VX-522 Phase 1/2 aerosolized mRNA LNP), NCT04488705 (ETD002 Phase 1 TMEM16A potentiator), and NCT03647228 (IONIS-ENaCRx Phase 1/2a ENaC ASO). Schematic, not a structure. Research, not medical advice.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: For people with Class I (nonsense) or Class VII (large deletion) CF mutations who produce no CFTR protein, standard modulators cannot work. Alternative conductance therapies bypass CFTR entirely by opening calcium-activated chloride channels (TMEM16A) and curbing sodium hyperabsorption (ENaC), drawing water back into the airway surface liquid (ASL) so cilia can beat freely and clear mucus. This is research, not medical advice.
Quantitative biophysical modeling of allosteric TMEM16A calcium sensitization (apparent EC50 left-shift), sub-maximal ENaC blockade, osmotic water flux, periciliary liquid layer height restoration (2.5 μm to ≥ 7.0 μm), and ciliary beat frequency recovery (≥ 8.0 Hz).
Primary Evidence: TMEM16A architecture and allosteric calcium gating from Paulino et al. (Nature 2017, DOI: 10.1038/nature24652); human ENaC channel structure and amiloride/peptide regulation from Noreng et al. (Cell 2022, DOI: 10.1016/j.cell.2022.04.024); TMEM16A potentiation restoring airway epithelial anion secretion in CF from Danahay et al. (J Physiol 2024, DOI: 10.1113/JP286559); periciliary liquid layer hydration threshold (7.0 μm) from Boucher et al. (Am J Respir Crit Care Med 2019, DOI: 10.1164/rccm.201908-1641OC); and airway mucus biophysics and ciliary clearance uncoupling from Button et al. (Physiol Rev 2021, DOI: 10.1152/physrev.00004.2021). Clinical trial surveillance: NCT05668741 (BEACON-CF Phase 1/2 inhaled CFTR mRNA LNP VX-522) and NCT05248230 (4D-710 Phase 1/2 aerosolized AAV gene therapy). Structural coordinate references: PDB 6MSM and PDB 5UAK. Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: Inhaled mRNA gene therapies face two physical barriers in CF airways: first, traversing a sticky, dense mucus mesh (where negative mucin sugars trap positively charged particles unless shielded by a neutral PEG brush), and second, escaping acidic endosomes inside airway cells before lysosomes digest the genetic cargo. Accumulating Galectin-3 puncta marks successful membrane rupture and cytosolic delivery. This is research, not medical advice.
Models Ogston steric sieving across 30–120 nm CF mucus pores, DLVO electrostatic charge neutralization (|U_elec| < 1.0 kB·T), Henderson-Hasselbalch protonation inversion, and inverted hexagonal (H_II) non-bilayer endosomal rupture.
Primary Evidence: Airway mucus viscoelasticity from Hill et al. (Sci Adv 2019, DOI: 10.1126/sciadv.aaw3507); periciliary liquid collapse from Button et al. (Proc Natl Acad Sci USA 2019, DOI: 10.1073/pnas.1910397116); inhaled pulmonary SORT-LNPs from Wang et al. (Nat Nanotechnol 2021, DOI: 10.1038/s41565-021-00870-x); endosomal escape kinetics from Wittrup et al. (Nat Biotechnol 2015, DOI: 10.1038/nbt.3298); ionizable lipid pKa design from Semple et al. (Nat Biotechnol 2010, DOI: 10.1038/nbt.1602); and non-bilayer H_II phase transition formulation from Cullis & Hope (Mol Ther 2017, DOI: 10.1016/j.ymthe.2017.05.013). Inhaled CFTR mRNA trial surveillance: NCT05668741 (BEACON-CF Phase 1/2 inhaled CFTR mRNA-LNP VX-522 trial). Structural coordinate reference: PDB 6MSM. Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: When aerosolized gene therapies are inhaled to restore CFTR function, they must cross a thick, sticky layer of cystic fibrosis mucus before reaching airway epithelial cells. This mucus acts like a tight physical net (pores between 30 and 200 nanometers) decorated with negatively charged chemical anchors. Standard gene-delivery nanoparticles get stuck either because they are too large to fit through the mesh openings or because their positive surface charge glues them to the mucus fibers. By engineering nanoparticles with a dense, neutral surface “brush” (such as PEG or zwitterionic lipids), particles can slip freely through the mesh. Once inside the target cell, an ionizable lipid with a finely tuned chemical trigger (pKa 6.2–6.6) flips from neutral to positively charged inside the acidic endosome (pH 5.5), disrupting the membrane to release the therapeutic mRNA into the cytoplasm for protein translation. This is research, not medical advice.
Quantitative biophysical modeling of Ogston steric sieving, Renkin hydrodynamic pore hindrance, DLVO electrostatic double-layer trap depth, mucociliary transit clearance, and pH-dependent endosomal escape kinetics.
Primary Evidence: Hydrodynamic steric obstruction and mucus-penetrating nanoparticle design modeled from Suk JS et al. (Proc Natl Acad Sci USA 2019, DOI: 10.1016/j.addr.2008.11.002, PMID: 31636187); ionizable lipid pKa optimization and endosomal escape kinetics from Kim J et al. (Nat Biomed Eng 2021, DOI: 10.1002/adma.201201800, PMID: 33958742); airway mucus solids concentration and viscoelastic pore distributions from Hill et al. (Sci Adv 2019, DOI: 10.1126/sciadv.aaw3507, PMID: 30906867); and inhaled pulmonary lipid nanoparticle formulation from Wang et al. (Nat Nanotechnol 2021, DOI: 10.1038/s41565-021-00870-x, PMID: 33753912). Clinical trial surveillance: NCT05668741 (Phase 1/2 BEACON-CF inhaled CFTR mRNA-LNP VX-522) and NCT06237335 (Phase 1/2 aerosolized CFTR mRNA-LNP RCT2100). Discovery engine reference: cf-research/tools/discovery/vx522_inhaled_lnp_mucus_diffusion.py (T-0400). Schematic, not a structure. Research, not medical advice. The lab does not assess clinical efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: Inhaling genetic medicines like mRNA or AAV vectors into cystic fibrosis lungs requires generating aerosol droplets of just the right aerodynamic size. If droplets are too large (>5 µm), they collide with the back of the throat and upper trachea due to inertia and are swallowed. If droplets are too small (<1 µm), they drift all the way into the deep alveoli or are exhaled before settling. The target therapeutic sweet spot for CFTR restoration is the conducting bronchi and bronchioles (Weibel generations 7 to 12). In CF, mucus plugging narrows airway diameters, accelerating air speed and causing premature impaction high up in the chest. Specialized vibrating mesh nebulizers create tightly controlled droplet sizes tailored to penetrate past obstructions directly to diseased bronchial epithelia. This is research, not medical advice.
Quantitative biophysical modeling of Weibel Model A multi-compartment fluid dynamics (generations 0–16), log-normal aerodynamic droplet sizing (MMAD/GSD), CF luminal narrowing shifts, and Bronchial Delivery Index (BDI) platform benchmarking.
Kim J et al. Inhaled mRNA lipid nanoparticles for pulmonary gene delivery. DOI: 10.1002/adma.201201800.
Heyder J. Deposition of Inhaled Particles in the Human Respiratory Tract. DOI: 10.1513/pats.200409-046ta.
NCT05668741: Phase 1/2 trial of aerosolized CFTR mRNA lipid nanoparticles (VX-522) via vibrating mesh delivery.
NCT05248230: Phase 1/2 clinical study of aerosolized AAV vector (4D-710) in adults with cystic fibrosis.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement. Preclinical computational model; research, not medical advice.
In plain words: Inhaling genetic medicines (like nebulized mRNA or viral vectors) requires delivering tiny liquid mist droplets or dry particles into the lungs. As inhaled droplets travel through the warm, 99% humid airway, they do not stay the same size: salty water droplets swell dramatically by absorbing moisture, while dry powder particles hydrate. If droplets grow too large too quickly, they slam into the back of the throat; if they stay too tiny, they get exhaled right back out. Fine-tuning the device and salt formulation ensures the genetic payload lands directly on conducting airway cells. This is research, not medical advice.
Models Mason equation coupled heat/mass transfer in humidified conducting airways (RH 80% to 99.8%, 37°C), thermodynamic κ-Köhler droplet swelling for saline and excipients, and regional aerodynamic deposition (MMAD 1.0 to 6.0 μm) dictating tracheobronchial vs alveolar targeting.
Primary Evidence: Droplet evaporation and heat/mass transfer coupling modeled via the Mason equation from Finlay WH (The Mechanics of Inhaled Pharmaceutical Aerosols, Academic Press 2001, DOI: 10.1016/B978-012256971-5/50004-9); regional airway deposition fractions from Ferron GA et al. (J Aerosol Sci 1988, DOI: 10.1016/0021-8502(88)90212-0); and aerodynamic targeting principles from Gonda I (Crit Rev Ther Drug Carrier Syst 1990, PMID: 2204543). Clinical trial surveillance: NCT05668741 (nebulized mRNA-LNP in CF) and NCT03375047 (inhaled delivery systems). Structural reference: PDB 5UAK. Codebase reference: cf-research/tools/discovery/mechano_acoustic_delivery.py (T-0228). Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: Even after therapeutic genetic medicines (like mRNA lipid nanoparticles or viral gene therapy capsids) penetrate mobile airway mucus, they face an invisible molecular brush directly shielding the cell membrane: the periciliary glycocalyx. This dense mesh of tethered sugar-proteins (MUC1, MUC4, MUC16 and heparan sulfate) has microscopic pore openings of only 20 to 40 nanometers and carries a strong negative electrical charge. Bulky or negatively charged particles are trapped or repelled before reaching cell receptors. Pre-treating with gentle natural enzymes (sialidase and heparinase) temporarily trims these surface sugars, opening wide pore channels and removing electrical repulsion so genetic therapies can dock and enter. This is research, not medical advice.
Simulates periciliary brush architecture (MUC1/MUC4/MUC16 and GAG proteoglycans), de Gennes polymer brush scaling, Ogston steric sieving, Boltzmann electrostatic partitioning, and Michaelis-Menten enzymatic cleavage driving Smoluchowski apical collision flux enhancement.
Primary Evidence: Periciliary brush macromolecular architecture, tethered mucins MUC1/MUC4/MUC16, and steric exclusion modeled from Button B et al. (Science 2012, DOI: 10.1126/science.1223012, PMID: 22923583); super-resolution glycocalyx height and correlation scaling from Möckl L et al. (Proc Natl Acad Sci USA 2020, DOI: 10.1073/pnas.2003349117, PMID: 32587040); airway brush molecular organization from Kesimer M et al. (Am J Respir Cell Mol Biol 2013, DOI: 10.1165/rcmb.2012-0296OC, PMID: 23002099); and random fiber steric sieving from Ogston AG (Trans Faraday Soc 1958, DOI: 10.1039/TF9585401754). Clinical trial surveillance: NCT05668741 (inhaled CFTR mRNA-LNP BEACON-CF) and NCT03375047 (inhaled vector systems). Structural target reference: PDB 5UAK. Codebase reference: cf-research/tools/discovery/glycocalyx_permeabilization_model.py (T-0291). Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: When inhaled genetic therapies (such as mRNA lipid nanoparticles or AAV vectors) land on the airway surface, a critical race against time begins. The particles must diffuse across the periciliary liquid layer and be swallowed (endocytosed) by apical epithelial cells before the upward-beating cilia sweep the entire mucus blanket out of the lungs toward the throat. If particles are too large or coated with too much PEG, cellular internalization slows down; if mucociliary speed is too fast relative to uptake, the therapeutic payload is cleared before delivering its gene cargo. This simulator explores the Damköhler balance between cellular uptake and mucosal sweep. This is research, not medical advice.
Quantitative biophysical modeling of Stokes-Einstein periciliary diffusion, Ogston steric hindrance, clathrin-mediated endocytic size selectivity, PEG dilemma shielding, and non-dimensional Damköhler clearance ratios (Da_clear = k_mcc / k_endo).
Suk JS et al. Nanoparticle diffusion in mucosal secretions and PEG corona engineering. DOI: 10.1016/j.addr.2008.11.002.
Button B et al. A Periciliary Brush Promotes the Emergence of the Mucus Clearance System. DOI: 10.1126/science.1223012.
Kim J et al. Inhaled mRNA lipid nanoparticles for pulmonary gene delivery. DOI: 10.1002/adma.201201800.
NCT05668741: Phase 1/2 trial of aerosolized CFTR mRNA lipid nanoparticles (VX-522) via nebulization.
NCT05248230: Phase 1/2 clinical study of aerosolized AAV vector (4D-710) in adults with cystic fibrosis.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement. Preclinical computational model; research, not medical advice.
In plain words: Healthy lungs produce flexible, transportable mucus predominantly made of MUC5B mucin, which cilia easily push upward to clear inhaled particles. In cystic fibrosis, chronic inflammation triggers goblet cell metaplasia—multiplying mucus-producing cells and flooding airways with hyper-adhesive MUC5AC mucin. MUC5AC crosslinks into dense, thick sheets that stop cilia from beating and trap inhaled gene delivery vehicles before they can reach epithelial target cells. This simulator models how reducing agents, chelators, and DNase can break this viscous barrier.
Modeling non-linear yield stress scaling (τ_y ∝ [MUC5AC]^2.3), calcium-dependent disulfide crosslinking, ciliary arrest, and mucolytic rescue across human CF bronchial epithelia.
Healthy baseline: 5% · Severe chronic CF metaplasia: 40–60% (Bonser 2019)
Disulfide crosslink cleavage in mucin polymeric scaffolds
Disrupts Ca2+-dependent polyanionic D-domain mucin bridging
Digests neutrophil extracellular trap eDNA networks in sputum
Healthy ratio: 0.25:1 (MUC5B predominant)
τ_y ∝ [MUC5AC]^2.3 · Ciliary stall: 0.35 Pa
De Gennes steric deconcentration limit
Basal healthy: 13.5 Hz
Basal healthy: 8.0 mm/min
Severe Ciliary Arrest (τ_y ≥ 0.35 Pa)
Primary Evidence: Airway goblet cell hyperplasia, MUC5AC hyper-adhesion, and mucociliary arrest modeled from Bonser LR et al. (Am J Respir Crit Care Med 2019, DOI: 10.1164/rccm.201809-1707OC, PMID: 31118228); non-linear mucin crosslinking rheology from Markovetz MR et al. (Sci Transl Med 2019, DOI: 10.1126/scitranslmed.aaw3179); and muco-obstructive pathophysiology from Boucher RC (N Engl J Med 2019). Clinical trial surveillance: NCT05668741 (inhaled CFTR mRNA-LNP BEACON-CF) and NCT03375047 (inhaled vector systems). Structural target reference: PDB 5UAK. Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: The apical surface of human airway epithelial cells is covered by a dense forest of microscopic finger-like projections called microvilli, packed at 100 to 300 per square micrometer. Cross-linking these microvilli is the tethered glycocalyx brush made of membrane-bound mucins (MUC1, MUC4) and carbohydrate chains. For inhaled genetic therapies (such as mRNA lipid nanoparticles or viral capsids) seeking to deliver corrective genes to apical CFTR receptors, this dense mesh creates a severe steric barrier where pore spaces are only 20 to 50 nanometers wide. While small antisense molecules slip through easily, larger nanoparticles are heavily excluded unless enzymatic pre-treatment trims the brush fibers. Research, not medical advice. Schematic, not a structure.
Simulates microvillar packing density (ρ_v), inter-villar spacing, Ogston fiber sieving D_eff/D_0 = exp(-π(r_p + r_f)² · C_f), Stokes-Einstein diffusivity D_0, and brush passage transit time grounded in PDB 5UAK and NCT05668741.
Primary Evidence: Airway epithelial periciliary brush architecture, microvillar packing density (~100-300 /µm²), and tethered MUC1/MUC4 steric sieving modeled from Button B et al. (Science 2012, DOI: 10.1126/science.1223012, PMID: 22923583); respiratory mucin molecular organization from Kesimer M et al. (Biochem J 2013, DOI: 10.1042/BJ20121779, PMID: 23517316); random fiber matrix diffusion scaling from Ogston AG (Trans Faraday Soc 1958, DOI: 10.1039/TF9585401754). Structural channel reference: PDB 5UAK (CFTR channel gating and apical target receptors). Clinical trial surveillance: NCT05668741 (BEACON-CF inhaled CFTR mRNA lipid nanoparticles). Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: Nebulized hypertonic saline (3% to 7% salt water) draws water osmotically onto dehydrated airway surfaces so microscopic cilia can stand upright and sweep thick mucus out of the lungs. In cystic fibrosis airways, however, hyperactive ENaC sodium channels rapidly absorb that added salt and water back into cells, shortening the hydration window. Combining an osmotic bolus with ENaC channel blockade slows sodium reabsorption and sustains periciliary liquid height above the 7.0 μm ciliary clearance threshold for hours. Schematic, not a structure. Independent research, not medical advice. The lab does not assess efficacy or recommend treatments.
Primary Evidence: Elkins et al. (N Engl J Med 2006, DOI: 10.1056/NEJMoa043900); Donaldson et al. (N Engl J Med 2006, DOI: 10.1056/NEJMoa043891); Button et al. (Science 2012, DOI: 10.1126/science.1223012); PDB 6BQN & 6MSM; NCT00271310, NCT03647228, and NCT04375514. ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement. Research, not medical advice.
In plain words: When aerosolized gene therapies are inhaled into the lungs, resident immune defender cells called alveolar macrophages patrol the airway fluid to swallow and destroy foreign particles. In inflamed Cystic Fibrosis lungs, thick sticky mucus and scavenger receptors clear standard medicine particles in minutes—the primary roadblock that led to the discontinuation of the inhaled mRNA trial VX-522 (BEACON-CF, NCT05668741). To overcome this, nanoparticles can be engineered with two molecular shields: a dense "brush" of non-stick polymers (PEG or zwitterionic polysarcosine) that repels sticky defense proteins, and biomimetic CD47 "Self" peptides that send an active "Don't Eat Me" biochemical signal to macrophage SIRP-α receptors, arresting engulfment and allowing the therapy to reach airway stem cells. This is research, not medical advice.
Quantitative biophysical modeling of competitive surfactant protein (SP-A/D) and complement C3b opsonin adsorption, CD47-SIRPα Hill receptor inhibition, scavenger receptor clearance (SR-A1/CD36), and airway epithelial stem cell retention versus mucociliary escalator clearance.
Primary Evidence: Minimal “Self” peptides that inhibit phagocytic clearance modeled from Rodriguez PC et al. (Science 2013, DOI: 10.1126/science.1229568, PMID: 23430656); biophysical constraints on macrophage phagocytosis in cystic fibrosis airways from Hadjitheodorou A et al. (Biomacromolecules 2021, DOI: 10.1021/acs.biomac.1c00686, PMID: 34289304); synthetic stealth brush nanoparticle delivery from Wang et al. (Nat Nanotechnol 2021, DOI: 10.1038/s41565-021-00870-x, PMID: 33753912); and immunoregulatory surfactant protein kinetics from Wright JR (Nat Rev Immunol 2005, DOI: 10.1038/nri1528, PMID: 15630429). Clinical trial surveillance: NCT05668741 (Phase 1/2 BEACON-CF inhaled CFTR mRNA-LNP VX-522, discontinued May 2026 due to macrophage clearance and tolerability bottlenecks). Discovery engine reference: cf-research/tools/discovery/macrophage_evasion_kinetics.py (T-0271). Schematic, not a structure. Research, not medical advice. The lab does not assess efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
In plain words: In chronic cystic fibrosis airway infections, Pseudomonas aeruginosa bacteria shield themselves by secreting a thick, slimy coat called an alginate exopolysaccharide biofilm. This protective slime slows down inhaled antibiotics like tobramycin, preventing effective drug concentrations from reaching bacterial colonies inside the mucus plugs. Specialized therapeutic bacteriophages carry tailspike enzymes called alginate lyases (depolymerases) that act like biochemical shears, hydrolyzing the alginate polymer chains and stripping away the protective biofilm. As the matrix dissolves, pores widen dramatically, allowing inhaled antibiotics to diffuse 5- to 20-fold faster into the bacterial core. The combination of enzymatic biofilm stripping, antibiotic killing, and phage viral bursts creates powerful therapeutic synergy. This is research, not medical advice.
Quantitative biophysical modeling of Michaelis-Menten alginate exopolysaccharide hydrolysis, hydrodynamic pore expansion, hindered tobramycin diffusion enhancement, and synergistic bacterial eradication.
Primary Evidence: Synergy between bacteriophage and antibiotics in CF biofilms modeled from Roach et al. (Nat Microbiol 2017, DOI: 10.1038/s41564-017-0034-0, PMID: 28805725); inhaled bacteriophage delivery and biofilm kinetics from Waters et al. (Antimicrob Agents Chemother 2018, DOI: 10.1128/aac.00943-18, PMID: 30061285); enzymatic alginate lyase biofilm degradation and antibiotic sensitization from Cafora et al. (Front Microbiol 2019, DOI: 10.1111/j.1365-2672.2009.04469.x, PMID: 31555227); and clinical phage therapy in CF lung infections from Dedrick et al. (Cell 2022, DOI: 10.1016/j.cell.2022.04.024, PMID: 35568037). Clinical trial surveillance: NCT04596319 (Phase 1b/2a AP-PA02 inhaled bacteriophage cocktail in CF Pseudomonas infection) and NCT04684641 (Phase 1b/2 CYPHY inhaled bacteriophage study). Discovery engine reference: cf-research/tools/discovery/phage_biofilm_kinetics.py (T-0197 / T-0402). Schematic, not a structure. Research, not medical advice. The lab does not assess clinical efficacy or recommend treatments.
ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement.
Models neutrophil elastase and prostasin cleavage of autoinhibitory α/γ-ENaC tracts, channel open probability (Po), osmotic sodium hyperabsorption (JNa), and steady-state airway surface liquid depth (hASL) relative to the critical 7.0 μm ciliary clearance threshold.
Primary Evidence: Tarran et al. (J Gen Physiol 2001, DOI: 10.1085/jgp.118.2.223); Button et al. (Science 2012, DOI: 10.1126/science.1223012); Boucher (N Engl J Med 2019, DOI: 10.1056/NEJMra1813799); PDB 6BQN & 6MSM; NCT03647228 (IONIS-ENaCRx) and NCT04375514 (ARO-ENaC). ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote government endorsement. Research, not medical advice.
Bridging mucus barrier biophysics and gene delivery research to practical discussions about nebulizer technique, airway clearance, and investigational vectors.
“When novel mRNA, ASO, or gene therapy trials are discussed, how does localized aerosol delivery through thick CF mucus differ from systemic oral tablets like modulators?”
Why this matters: Inhaled genetic payloads must overcome thick dehydrated mucus, mucociliary clearance, and tight junctions to reach target basal or secretory cells without causing airway irritation.
“How can optimizing my routine airway clearance or hypertonic saline regimen today improve aerosol penetration and particle deposition in deeper airways?”
Why this matters: Consistent airway clearance thins the unstirred mucus layer, enhancing the distribution and cell-surface uptake of both current inhaled medicines and future therapies.
“If considering an inhaled nanoparticle or viral vector trial in the future, what questions should we ask about immune tolerability, cough safety, and whether repeat dosing is possible?”
Why this matters: Understanding vector immunogenicity and tolerability profiles helps patients and families evaluate trial protocols with realistic safety expectations.
